Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852803 | 0.79 | APLNR (0.45) | APLNRRAB9AMAPTSMN1; SMN2CCR1 | |
| SCHEMBL1403879 | 0.77 | ALDH1A1 (0.40) | APLNRRAB9AMAPTALDH1A1POLB | |
| SCHEMBL5047396 | 0.77 | APLNR (0.48) | APLNRRAB9AMAPTSMN1; SMN2POLB | |
| SCHEMBL217899 | 0.77 | AGBL2 (0.37) | APLNRRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL19425889 | 0.74 | APLNR (0.55) | APLNRRAB9AMAPTCCR1CCR5 | |
| SCHEMBL24967349 | 0.73 | IKBKB (0.35) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL15780518 | 0.73 | APLNR (0.41) | APLNRRAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10382421 | 0.73 | ATM (0.47) | APLNRRAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21015648 | 0.73 | ALDH1A1 (0.33) | HDAC6ALDH1A1TP53KDM4EHSD17B10 | |
| SCHEMBL15148333 | 0.73 | APLNR (0.41) | APLNRRAB9AMAPTSMN1; SMN2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137329-A1 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023114198-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114200-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3722284-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3541792-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| EP-2738163-A1 | AMIDINE COMPOUND OR SALT THEREOF | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-06-04 | — | — | EP | disclosed |
| EP-2738163-A1 | AMIDINE COMPOUND OR SALT THEREOF | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013139822-A1 | NOVEL BISOXIME MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| EP-2641901-A1 | Novel microbiocides | Syngenta Participations AG. (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013018735-A1 | AMIDINE COMPOUND OR SALT THEREOF | 大正製薬株式会社 (JP) | 2013-02-07 | — | — | WO | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | APLNR 3544/4885RAB9A 2112/4885MAPT 4566/4885 |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | TBXA2R, AGTR1, APLNR | APLNR 3/4885RAB9A 890/4885MAPT 4334/4885 |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | ERG28, ARG1, THEM6 | APLNR 1620/4885RAB9A 1363/4885MAPT 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.